Stockpolly
Search
Delisting risk
MBIO · NASDAQ · Biotechnology

Mustang Bio (MBIO)

Develops a combined oncolytic-virus and CAR T treatment for recurrent brain tumors.

$0.5473
At close−0.00 (−0.15%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue001000000000
Gross profit00−1000000000
1095911011111
Research & development1074400100000
221210111111
General & administrative221210111111
Other expenses−100301−20−1000
Operating income−10−9−5−9−1−10−1−1−1−1−1
000000000000
Interest income000000000000
Interest expense000000000000
Other non-operating income030−300000000
Income before tax−10−9−5−8−1−10−10−1−1−1
Net income from continuing operations−10−9−5−8−1−10−10−1−1−1
Net income−10−9−5−8−1−10−10−1−1−1
EPS, basic−$1.23−$0.93−$0.46−$0.94−$0.16−$0.95−$0.05−$0.13−$0.08−$0.07−$0.14−$0.16
EPS, diluted−$1.23−$0.93−$0.46−$0.94−$0.16−$0.95−$0.05−$0.13−$0.08−$0.07−$0.14−$0.16
Weighted average shares, basic8911999666777
Weighted average shares, diluted8911999666777
EBITDA−10−11−4−6−1−10−10−1−1−1
Depreciation & amortization001000000000
EBIT−10−11−5−6−1−10−10−1−1−1